Advertisement.

GBIM Projected Dividend Yield

GlobeImmune, Inc ( OTCBB : GBIM )

GlobeImmune is a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen® platform. Co. has three Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. Co.'s infectious disease product candidates are: GS-4774 for hepatitis B infection; GI-19000 for tuberculosis; GI-2010 for human immunodeficiency virus; and GI-18000 for hepatitis D infection. Co.'s oncology product candidates are: GI-6207 for medullary thyroid cancer; GI-6301 for chordoma; and GI-4000 for resected pancreas cancer, non-small cell lung cancer, and colorectal cancer.

20 YEAR PERFORMANCE RESULTS

GBIM Dividend History Detail
GBIM Dividend News
GBIM Competitors News

# of Shares: 0

Closing Price: 0.00

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000